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Serum renin and major adverse kidney
events in critically ill patients: a multicenter
prospective study
Alexander H. Flannery1,2, Victor Ortiz‑Soriano3, Xilong Li4, Fabiola G. Gianella5, Robert D. Toto5,6,
Orson W. Moe5,6, Prasad Devarajan7, Stuart L. Goldstein7 and Javier A. Neyra3,5*

Abstract
Background: Preliminary studies have suggested that the renin-angiotensin system is activated in critical illness and
associated with mortality and kidney outcomes. We sought to assess in a larger, multicenter study the relationship
between serum renin and Major Adverse Kidney Events (MAKE) in intensive care unit (ICU) patients.
Methods: Prospective, multicenter study at two institutions of patients with and without acute kidney injury (AKI).
Blood samples were collected for renin measurement a median of 2 days into the index ICU admission and 5–7 days
later. The primary outcome was MAKE at hospital discharge, a composite of mortality, kidney replacement therapy, or
reduced estimated glomerular filtration rate to ≤ 75% of baseline.
Results: Patients in the highest renin tertile were more severely ill overall, including more AKI, vasopressor-depend‑
ence, and severity of illness. MAKE were significantly greater in the highest renin tertile compared to the first and
second tertiles. In multivariable logistic regression, this initial measurement of renin remained significantly associated
with both MAKE as well as the individual component of mortality. The association of renin with MAKE in survivors was
not statistically significant. Renin measurements at the second time point were also higher in patients with MAKE. The
trajectory of the renin measurements between time 1 and 2 was distinct when comparing death versus survival, but
not when comparing MAKE versus those without.
Conclusions: In a broad cohort of critically ill patients, serum renin measured early in the ICU admission is associated
with MAKE at discharge, particularly mortality.
Keywords: Renin, Acute kidney injury, Major adverse kidney events, Critical illness, Biomarker, Renin angiotensin
system
Background
The renin-angiotensin system (RAS) is increasingly recognized to be perturbed during critical illness. The complexity of this system, including circulatory, tissue-level,
and intra-cellular actions, as well as both traditional and
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counter-regulatory axes, makes it difficult to simply classify the RAS as activated or insufficiently activated in
critical illness; rather, it is dysfunctional [1]. RAS peptide analysis in vasodilatory shock [2] and acute respiratory distress syndrome [3] have strongly suggested a state
of reduced angiotensin converting enzyme (ACE) and
ACE2 function, respectively, which influences both the
traditional and counter-regulatory axes of the RAS. Furthermore, reduced ACE and ACE2 function are associated with acute kidney injury (AKI) [4] and mortality [3],
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respectively, in critically ill patients. Biochemical evaluation of the RAS requires careful biospecimen collection
and sophisticated analytical techniques [5]. However,
upstream in the complex milieu of RAS peptide metabolism, renin plays a rate-limiting step in the conversion
of angiotensinogen to angiotensin I, and is a far more
readily available lab test for clinicians to consider at the
bedside.
Recently, a single center study showed that plasma
renin outperformed lactate in prognostic value for intensive care unit (ICU) mortality [6]. Subsequently, a small,
single center study found no association of plasma renin
with mortality, but did note plasma renin to be much
higher with worsening AKI [7]. Given the potential of
renin to serve as a novel biomarker for adverse kidney
outcomes and mortality in critically ill patients, we conducted a multicenter prospective study to examine the
association of serum renin with mortality and adverse
kidney events in a larger and heterogeneous cohort of
critically ill adult patients.

Methods
This was a prospective, multicenter study of ICU
patients from two academic medical centers. Patients
were recruited sequentially from each site: University
of Texas Southwestern (2015–2017) and the University of Kentucky (2017–2019). Adult patients ≥ 18 years
old admitted to surgical, medical, or cardiac ICUs with
a documented baseline estimated glomerular filtration
rate (eGFR) ≥ 60 mL/min/1.73 m2 were eligible for inclusion. eGFR was calculated using the most recent outpatient serum creatinine in the 6 months prior to admission
using the CKD-Epidemiology Collaboration equation [8].
Patients with end stage kidney disease (ESKD), evidence
of AKI prior to ICU admission, uroepithelial tumors, or
prior solid organ transplant were excluded.
The study purposefully included ICU patients with
incident AKI based on Kidney Disease: Improving
Global Outcomes (KDIGO) serum creatinine or urine
output stage ≥ 2 criteria and ICU patients without AKI
[9]. Blood samples were collected within the first 3 days
of ICU admission (~ 24 h after AKI diagnosis for those
with AKI). A second set of blood samples were collected
5–7 days following the initial collection. Demographic
and comorbidity data were collected from the patient’s
medical record for each enrolled patient. ICU-centric
therapies were assessed, including the need for mechanical ventilation and vasopressor support. Patients’ comorbidities and severity of illness were further assessed with
the Charlson Comorbidity Index [10] and Acute Physiology and Chronic Health Evaluation (APACHE) II score,
respectively [11].
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The primary outcome of the study was a major adverse
kidney event (MAKE) by hospital discharge, defined as
death, kidney replacement therapy (KRT) dependence
at hospital discharge, or a reduction in eGFR to ≤ 75% of
baseline at hospital discharge [12]. Each sub-component
of the primary composite outcome was also assessed separately. Additional secondary outcomes included need
for inpatient KRT, duration of mechanical ventilation,
and ICU and hospital length of stay.
The study was approved by the institutional review
boards at both participating centers. Patients, or their
legally authorized representatives, provided written,
informed consent for participation in the study.
Laboratory analysis

Serum samples were processed within 45–60 min of
collection, centrifuged at 1000g at 4 °C for 10 min, and
stored at − 80 °C. Renin measurements were obtained
using the active renin ELISA kit from DRG Diagnostics
(Kit Reference ID: EIA-5125). The assay dynamic range
is 0.80–128.0 pg/ml. The intra-assay CV is 2.4% and
the inter-assay CV is 3.7%. The expected normal values in the serum or plasma range from 2.5 to 49.3 pg/
ml. Neutrophil gelatinase-associated lipocalin (NGAL)
measurements were obtained on a Siemens BNII using a
particle-enhanced turbidimetric immunoassay from BioPorto (The NGAL Test, Kit Reference ID: ST001). Most
samples (> 90%) were measured on the first freeze–thaw
cycle. All other laboratory data were extracted from
routine measurements available in the electronic health
record.
Statistical analysis

The first timepoint of renin measurements were assessed
in tertiles. Medians and interquartile range and frequency (proportions) were used to provide descriptive
statistics for the cohort. Comparisons among groups
were done with Kruskal–Wallis (3 groups) or Wilcoxon
rank-sum (2 groups) for continuous data and chi-square
test for categorical data.
For the primary outcome of MAKE, a logistic regression model was constructed using renin tertiles as the
independent variable of interest. Additional variables
to include in the model were identified by the study
group based upon their hypothesized ability to influence
MAKE and according to imbalances in clinical parameters among renin tertiles that could potentially influence
outcome. Given prior data demonstrating a strong association of serum NGAL with MAKE, including NGAL
outperforming serum creatinine [13, 14], we used NGAL
to adjust for the presence and severity of kidney injury.
NGAL (and renin in the sensitivity analysis) were logtransformed due to the skewness of the data. Additional
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variables included in the model were: age, sex, race,
baseline eGFR, Charlson Comorbidity Index, ICU type,
study site, and non-renal APACHE II. In a pre-planned
sensitivity analysis, renin was subsequently analyzed as
a continuous variable in the logistic regression model
for MAKE. Clinical parameters that were otherwise captured in scoring systems such as the Charlson Comorbidity Index and APACHE II were not included in order to
avoid collinearity, which was assessed in the final models
using variance inflation factors. When analyzing individual components of the MAKE outcome with logistic
regression, we used backward stepwise regression (p < 0.2
threshold) given that we anticipated the reduced number
of events to not accommodate the number of covariates
used in the primary model. Finally, a mixed linear model
was used to examine repeated measures analysis of

serum renin levels between the two time points and their
association with MAKE and the individual component of
mortality.
A two-sided p value ≤ 0.05 was considered statistically
significant. Stata (StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC)
and SAS 9.4 (SAS Institute, Cary, NC) were used for all
statistical analyses.

Results
From January 2015 to September 2019, 280 patients
were enrolled in this prospective study with available
blood samples for analysis. The median time from ICU
admission to initial sample collection in the cohort was
2 (1–3) days. Baseline patient characteristics according
to tertiles of serum renin are shown in Table 1. Seven

Table 1 Patient characteristics by renin tertile at first measurement
Patient demographic

Tertile 1 (n = 94)

Tertile 2 (n = 93)

Tertile 3 (n = 93)

p value
< 0.001

Serum renin (pg/ml)

7.2 (3.1–12.4)

40.7 (29.9–60.1)

355.3 (180.4–1032.1)

Age (years)

61.5 (47–71)

59 (50–66.5)

53 (40.5–64)

0.004

Sex (% male)

53 (56.4%)

53 (57.0%)

57 (61.3%)

0.760

White

75 (79.8%)

74 (79.6%)

71 (76.3%)

Black

10 (10.6%)

9 (9.7%)

7 (7.5%)

Other

9 (9.6%)

10 (10.8%)

15 (16.1%)

77.7 (65.1–95.3)

88.0 (75.3–105.2)

89.8 (72.8–113.4)

Surgical

46 (48.9%)

37 (39.8%)

18 (19.4%)

Medical

33 (35.1%)

34 (36.6%)

48 (51.6%)

Cardiac

15 (16.0%)

22 (23.7%)

27 (29.0%)

Diabetes (%)

23 (24.5%)

26 (28.0%)

25 (26.9%)

0.858

Hypertension (%)

50 (53.2%)

47 (50.5%)

49 (52.7%)

0.928

Heart failure (%)

20 (21.3%)

20 (21.5%)

31 (33.3%)

0.096

Race (%)

Weight (kg)

0.649

ICU (%)

0.006
0.001

Liver disease (%)

8 (8.5%)

14 (15.1%)

25 (26.9%)

0.003

Cancer (%)

28 (29.8%)

23 (24.7%)

22 (23.9%)

0.613

Baseline serum creatinine (mg/dl)

0.8 (0.7–0.9)

0.8 (0.7–1.0)

0.9 (0.8–1.0)

0.274

Baseline eGFR (ml/min/1.73 m2)

89 (78–101)

88 (75–100)

91 (77–105)

0.746

Non-renal APACHE II

15 (10–20)

17 (10.5–22)

19 (12.5–24)

Non-renal SOFA

5 (2–8)

5 (2–9)

8 (5–12)

0.009
< 0.001

Charlson comorbidity index

3 (2–5)

3 (2–4)

4 (2–6)

0.566

Number of vasopressors/inotropes

0 (0–1)

1 (0–2)

2 (1–3)

< 0.001

Mechanical ventilation (%)

44 (46.8%)

47 (50.5%)

62 (66.7%)

Serum creatinine at first renin measurement (mg/dl)

0.8 (0.7–1.5)

1.3 (0.8–2.4)

1.8 (0.9–3.3)

< 0.001

Acute kidney injury (%)

< 0.001

30 (31.9%)

52 (55.9%)

63 (67.7%)

Stage 2a

2 (6.7%)

12 (23.1%)

8 (12.7%)

Stage 3a

28 (93.3%)

40 (76.9%)

55 (87.3%)

119 (69–288)

226 (88–421)

240 (80–757)

Serum NGAL at first renin measurement (ng/ml)

ICU intensive care unit, eGFR estimated glomerular filtration rate, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure
assessment, NGAL neutrophil gelatinase-associated lipocalin
a

As percent of all acute kidney injury cases

0.015

0.018
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patients with AKI were receiving angiotensin converting enzyme inhibitors or angiotensin receptor blockers
at enrollment. Serum renin values were markedly different in the three tertiles: first tertile 7.2 (3.1–12.4) pg/
ml, second tertile 40.7 (29.9–60.1) pg/ml, and third tertile 355.3 (180.4–1032.1) pg/ml. While baseline kidney
function was similar between the renin tertiles, patients
in the highest tertile tended to more often be in the
medical ICU, have liver disease, and be more acutely
ill as suggested by non-renal APACHE II, non-renal
SOFA, number of vasopressors/inotropes, requirement
for mechanical ventilation, and have more severe AKI
as assessed by serum creatinine and NGAL. The initial
measurements of serum renin and NGAL were more
than two-fold higher (p < 0.001 for both) in patients
with AKI compared to those without AKI (Additional
file 1: Table S1). At 5–7 days following this initial measurement, both renin (p = 0.046) and NGAL (p < 0.001)
remained higher in patients with AKI versus those
without AKI (Additional file 1: Table S1). There was no
significant interaction between the first serum renin
measurement, AKI status, and the outcome of MAKE
(p for interaction = 0.251).

For the primary outcome of MAKE assessed at hospital discharge, increasing tertiles of serum renin were
strongly associated with a greater frequency of MAKE
events (p < 0.001) (Table 2). Increasing tertiles of serum
renin were also associated with worse secondary outcomes including need for inpatient KRT, duration of
mechanical ventilation, and ICU and hospital lengths of
stay (p ≤ 0.003 for all) (Table 2). Patients experiencing
MAKE had significantly higher serum renin and NGAL
concentrations at both timepoints (p = 0.003 or less
for all) (Additional file 1: Table S2). When stratified by
inpatient mortality, serum renin and NGAL measurements were again higher at both time points measured
in patients who died compared to those who survived
(p < 0.001 for all) (Additional file 1: Table S3). Serum
renin concentrations are shown in Fig. 1.
In the multivariable logistic regression model for
MAKE, the second [OR 2.51 (95% CI 1.08–5.80)] and
third [OR 2.33 (95% CI 1.01–5.44)] renin tertiles were
independently associated with MAKE when compared
to the first renin tertile (Table 3). When the same model
was analyzed using serum renin as a continuous variable rather than categorization into tertiles, serum renin

Table 2 Clinical outcomes by renin tertiles
Outcome

Tertile 1 (n = 94)

Tertile 2 (n = 93)

Tertile 3 (n = 93)

p value

MAKE at hospital discharge (%)

23 (24.5%)

36 (38.7%)

47 (50.5%)

0.001

Hospital mortality

8 (8.5%)

10 (10.8%)

25 (26.9%)

–

KRT at discharge

1 (1.1%)

3 (3.2%)

4 (4.3%)

–

Discharge eGFR ≤ 75% of baseline

14 (14.9%)

23 (24.7%)

18 (19.4%)

–

Inpatient KRT (%)

8 (8.5%)

16 (17.2%)

32 (34.4%)

< 0.001

Duration of mechanical ventilation (days)

0 (0–3)

1 (0–6)

2 (1–8)

0.003

ICU length of stay (days)

4 (2–9)

6 (3–11)

8 (4–18)

0.001

Hospital length of stays (days)

9 (5–17)

10 (5–18)

14 (8–22)

0.002

Primary outcomes

Secondary outcomes

MAKE major adverse kidney event, KRT kidney replacement therapy, eGFR estimated glomerular filtration rate, ICU intensive care unit

Fig. 1 Serum renin stratified by presence of acute kidney injury, major adverse kidney events, or inpatient mortality
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Table 3 Multivariable logistic regression model for major
adverse kidney events at the time of hospital discharge by renin
tertiles
Variable

Odds ratio with 95%
confidence intervala

p value

Renin tertile (vs. first tertile)
Second tertile

2.51 (1.08–5.80)

0.032

Third tertile

2.33 (1.01–5.44)

0.050

Age (vs. first quartile)
Second quartile

0.32 (0.12–0.86)

0.023

Third quartile

0.31 (0.10–0.95)

0.040

Fourth quartile

0.30 (0.08–1.11)

0.071

0.63 (0.32–1.25)

0.188

Black

2.30 (0.74–7.15)

0.150

Other

1.20 (0.39–3.68)

0.748

Sex (male vs. female)
Race (vs. white)

Baseline eGFR, per 1 ml/min/1.73 m2

1.02 (0.99–1.04)

0.173

Charlson comorbidity index, per 1-unit 1.64 (1.35–2.00)

< 0.001

ICU (vs. surgical)
Medical

2.82 (1.30–6.12)

0.009

Cardiac

2.12 (0.69–6.48)

0.189

Site (UK vs. UTSW)

1.28 (0.54–3.02)

0.572

Non-renal APACHE II, per 1-unit

1.02 (0.98–1.06)

0.246

NGAL, per 1-log unit

2.93 (2.02–4.23)

< 0.001

eGFR estimated glomerular filtration rate, ICU intensive care unit, UK University
of Kentucky, UTSW University of Texas Southwestern, APACHE II Acute Physiology
and Chronic Health Evaluation II, NGAL neutrophil gelatinase-associated
lipocalin
a

Fixed model developed using hypothesized predictors of outcome and
clinically relevant imbalances in renin tertiles

remained significantly and independently associated with
MAKE (OR 1.19 (95% CI 1.01–1.41) for 1-log unit higher
serum renin) (Additional file 1: Table S4). In the multivariable logistic regression model for inpatient mortality,
the third renin tertile, but not the second, was associated
with in-hospital mortality: OR 2.98 (95% CI 1.03–8.61)
(Additional file 1: Table S5). When the stepwise logistic
regression model was limited to evaluation of MAKE in
survivors only (KRT and reduced eGFR), renin was not
significantly associated with MAKE (Additional file 1:
Table S6). In a sensitivity analysis of the primary model,
a 50% reduction in the eGFR threshold for MAKE rather
than 25% reduction was evaluated (event numbers for the
different definitions shown in Additional file 1: Table S7).
Using the 50% eGFR reduction threshold, renin tertiles
did not significantly associate with MAKE at discharge
(Additional file 1: Table S8).
Renin as a continuous variable was further examined
in a mixed linear model with repeated measures analysis. The estimates and 95% CI were exponentiated back
to geometric means and 95% CI presented. In the group
of patients not experiencing MAKE, renin decreased

significantly over time: geometric means decreased
from 26 to 12 (p < 0.001) (Additional file 1: Table S9). In
the group of patients experiencing MAKE, renin also
decreased over time: geometric means decreased from 81
to 39 (p = 0.002). There was no significant difference (no
interaction) between groups for renin decrease over time
for the outcome of MAKE (p = 0.745). In contrast, when
analyzing mortality, there was an interaction (p = 0.041)
between the mortality and survival groups for renin
decrease over time (Additional file 1: Table S10). Patients
surviving had a decreasing serum renin trend whereas
patients that died had similar renin concentrations at the
second time point compared to the first measurement.
To investigate the relative contribution of both AKI
and hemodynamic instability to elevations in serum
renin concentration, a 2 × 2 table with row and column
comparisons is shown in Additional file 1: Table S11.
The receipt of vasopressors during the ICU admission
was associated with elevated renin concentrations measured at the first time point, independent of AKI status.
In addition, patients with AKI had higher serum renin
concentrations compared to patients without AKI, independent of the need for vasopressors during the ICU
admission, although this comparison did not reach statistical significance.

Discussion
In this multicenter prospective study, serum renin
measured within the first days of ICU admission was
significantly associated with MAKE. In particular, the
association with hospital mortality appears to be the
strongest association from the individual components
of MAKE. This study adds to the body of literature suggesting that the RAS, at least in the upstream portion
represented by serum renin, is activated in critical illness and is associated with mortality and adverse kidney
outcomes. The renin measurements in our study, particularly for patients with AKI and those experiencing
MAKE, were much higher than their comparators, and at
times, 10–100 × fold higher in comparison to renin levels
from other patients in the study and the expected normal
serum values.
The prior work in this field has primarily focused on
critically ill patients with sepsis. In a cohort study of 30
critically ill patients with severe sepsis compared to 10
healthy controls, plasma renin activity (PRA) and angiotensin II were higher at 8- and 24-h following the recognition of organ dysfunction. Furthermore, elevated PRA
was negatively correlated with microvascular function
as assessed using the reoxygenation rate of skeletal muscle to reactive hyperemia using near infrared spectroscopy [15]. While hypotension is known to elicit renin
release, the mean arterial pressure in this study was not
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significantly correlated with PRA, suggesting that activated RAS in severe sepsis is due to altered explanations,
perhaps either causally or even compensatory to microvascular dysfunction and reduced tissue perfusion [15].
Renin is also known to be released in response to sympathetic activation and metabolic alterations, which are
common in critically ill patients in the ICU [16].
In a prospective study of 41 patients with septic shock
requiring ≥ 0.25 mcg/kg/min of norepinephrine, plasma
renin was much higher in patients with KDIGO stage
2 or 3 AKI as compared to KDIGO stage 1 or no AKI
[7]. This relationship has been difficult to tease apart
as plasma renin is also moderately-strongly correlated
with severity of illness scores, vasopressor dose, lactate,
and similar markers [7]. Our results demonstrate that
even controlling for these severity of illness indicators as
well as kidney injury using serum NGAL, serum renin
remains associated with MAKE. The challenge of further
work in the field remains to ascertain whether elevated
renin in the setting of critical illness remains a signal of
damage at the microcirculatory level, or if elevated circulatory renin exerts untoward RAS-mediated effects that
worsen the cycle of morbidity in AKI and other critical
illness syndromes.
The concept of renin as a marker of tissue perfusion
was recently tested in a single center study of 20 patients
with 112 arterial blood samples and confirmed plasma
renin was not affected by diurnal variation, medications,
or removal by continuous renal replacement therapy
(CRRT) [6]. Similar to our results, the authors demonstrated renin levels with extreme elevation (> 100-fold
upper limit of normal) in patients that did not survive.
Additionally, renin outperformed lactate for predicting ICU mortality [6]. Further, the value of repeated
measures of renin in critical care settings remains unexplored. In our study, we noted that patients whose renin
serum concentrations did not decrease by the second
time measurement were more likely to die compared to
surviving patients whose renin serum concentrations
decreased. This difference in trajectories of the serum
renin concentration was notable for mortality, but not for
MAKE. However, in cardiac surgery patients, the change
in serum renin concentrations from pre- and post-operation were recently shown to predict AKI better than the
postoperative renin concentration alone [17]. These data
all support the potential utility of repeated measures of
circulatory renin.
Importantly, the assay technique for serum renin could
significantly impact the findings. Previous literature uses
both PRA and direct measurement of renin, both of
which have trade-offs in their assessment. PRA results
may be dependent on angiotensinogen which could be
altered by comorbidities or medications in critically ill
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patients, and also has shown inter-laboratory variability
[6, 18]. The measurement of renin in our study is unique
from prior literature in this area in that the assay measures and directly quantifies active renin concentrations
and shows low cross-reactivity for the precursor of renin,
pro-renin [6]. While it has been shown that in stressed
states, the renin release far exceeds increases in prorenin
and that longer stimuli (i.e. not an acute stimuli) are
required to impact prorenin levels, previous work measuring total renin (renin and pro-renin) has been unable
to distinguish the specific molecular increase of renin in
critical illness [19, 20]. Our results confirm that active
renin is elevated, and at times markedly elevated, in those
patients with mortality and kidney injury from a broad
etiology of critical illness syndromes. Interestingly, the
prorenin receptor (PRR) binds both renin and prorenin,
and may induce inflammatory and profibrotic gene
expression via angiotensin-independent extracellular-signal-regulated kinase 1 (ERK1), ERK2, and p38 mitogenactivated protein kinase (MAPK) signaling pathways [21,
22]. This may provide yet another possible mechanism
for renin to function in a causal detrimental pathway in
critical illness rather than a marker of illness alone [21,
22].
The statement that the RAS is over-activated in critical
illness may, however, be an over-simplification of a complex pathway. In a secondary analysis of the Angiotensin
II for the Treatment of High-Output Shock (ATHOS-3)
trial enrolling patients with refractory vasodilatory shock,
significant ACE deficiency was hypothesized based on
elevated angiotensin I: angiotensin II ratios of peptides
[2]. Renin concentrations were shown to positively correlate with this angiotensin I: angiotensin II ratio, suggesting that renin could be a surrogate marker in vasodilatory
shock for a relative angiotensin II deficiency [23]. Renin
concentrations rapidly fell in the group given exogenous
angiotensin II, which supports this hypothesis [23]. Similar to our findings, renin was significantly associated with
mortality in the ATHOS-3 study [23]. This concept of
deficient angiotensin II signaling has been further suggested in recent reports of sepsis-associated AKI [24].
Based on these conflicting reports of RAS over-activation throughout the traditional RAS axis [15], as well as
those reviewed here suggesting incomplete activation in
the traditional RAS axis, this may be an indication that
different RAS endotypes exist in critical illness. If this is
indeed the case, measuring renin is much closer to bedside application than the technically challenging measurement of angiotensin peptides [5].
Strengths of this study include its prospective nature,
standardized biospecimen collection at two time
points, multicenter design, ruling out the influence
of chronic kidney disease on the RAS by requirement
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of documented baseline eGFR ≥ 60 mL/min/1.73 m2,
careful consideration of covariates known to influence
MAKE, measurement of active renin (as opposed to
renin and prorenin), and broad generalizability to a range
of critically ill patients. To our knowledge, this is the largest study to date evaluating serum or plasma renin concentrations and outcomes in critically ill patients.
Our study also has important limitations. Due to the
relatively large number of mortality events contributing to MAKE, we may have been under powered to
detect an association with the kidney-specific outcomes
in those patients surviving the hospital admission. This
limitation is also suspected in the sensitivity analysis for
MAKE using a 50% eGFR reduction from baseline where
the number of eGFR events contributing to MAKE was
reduced by almost half from the primary analysis. We
also used a singular race-based eGFR estimate (assessed
as ≤ 75% of baseline or not) to adjudicate part of the
MAKE outcome. In general, eGFR equations were developed for evaluation of kidney functional status at steady
state and are currently under revision by professional
societies for their inclusion of race, which may have
implications for studies using eGFR as a component of an
outcome measure in subacute settings [25]. Importantly,
our study did not enroll any patients with KDIGO stage
1 AKI, an important group of patients with potentially
reversible kidney injury in clinical practice. However, the
latter is also advantageous to eliminate the confounding effect of pre-renal azotemia as intrinsic AKI. While
we adjusted for hemodynamic instability with non-renal
APACHE II scores in multivariable modeling, as well
as investigated the impact of vasopressor receipt while
in the ICU on serum renin concentrations in additional
analysis, future work would benefit from precise measurements of vasopressor support in order to disentangle
the contribution of shock (and vasopressor support) from
AKI in terms of elevations in serum renin concentrations
in critically ill patients. Additionally, RAS alterations in
various diseases such as sepsis and post-operative conditions may be unique, along with potential age and sex
differences in the RAS that will be important avenues
of future research [26, 27]. While a small proportion of
patients were receiving RAS modulating drugs at enrollment, the extent of pre-hospital use of RAS modulating drugs in this cohort is unknown. Even though the
medications may have been stopped for several days
before biospecimen collection, their impact on the renin
response in critical illness is unclear. Finally, given the
complexity of biospecimen collection in critically ill
patients, renin measurements were not always obtained
within the first 3 days of ICU admission, which may have
shed additional light on temporal findings of the RAS in
early stages of critical illness.
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Conclusions
In a broad cohort of critically ill patients admitted to
the ICU, early measurement of serum renin was significantly and independently associated with MAKE
assessed at hospital discharge. The association appears
to be particularly strong for the relationship between
higher serum renin measurements and inpatient mortality. Further studies are needed to elucidate the value
of renin as a surrogate pathobiologic marker of microcirculatory function during critical illness.
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